Evidence map›Paper›PMID 40267363›Full record

ReviewDiabetes care2025

Is the Current Lifestyle Modification Approach to Diabetes Prevention in the U.S. a Success?

Justin B Echouffo-Tcheugui, Rosette J Chakkalakal, Mohammed K Ali

Abstract readReview
In one paragraph

Review in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Justin B Echouffo-TcheuguiDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, MD.ORCID 0000-0002-8460-1617
Rosette J ChakkalakalDepartment of Medicine, Emory School of Medicine, Emory University, Atlanta, GA.
Mohammed K AliDepartment of Family and Preventive Medicine, Emory School of Medicine, Emory University, Atlanta, GA.ORCID 0000-0001-7266-2503

Funding

Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Putting Telehealth to the Test: An Evaluation of the Use of Telehealth to Increase the Population-Level Impact of an Employer-Based Diabetes Prevention ProgramR01DK120814 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CHAKKALAKAL, ROSETTE J · 2019 to 2023
$2.5M
Establishing the Pathways Between Diabetes and Cardiac Dysfunction: Epidemiology, Biomarkers, and ImagingK23HL153774 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ECHOUFFO TCHEUGUI, JUSTIN BASILE · 2020 to 2024
$991k
NHLBI NIH HHS K23 HL153774NIDDK NIH HHS 75D30120P0742NIDDK NIH HHS P30 DK111024NIDDK NIH HHS P30DK111024NIDDK NIH HHS R01 DK120814NIDDK NIH HHS R01DK120814
6 · The paper itself

Abstract

Prediabetes is an intermediate stage between normal glycemia and diabetes and is highly prevalent, especially in adults, but is also increasingly common in young individuals. Randomized clinical trials have demonstrated that lifestyle modification is cost-effective in preventing diabetes. Implementation studies showed the feasibility of delivering real-world structured lifestyle modification programs adapted from the U.S. Diabetes Prevention Program trial. However, the current approach to diabetes prevention in the U.S. has been largely inadequate thus far, as evidenced by the stagnant numbers of people with prediabetes and the growing number of those with diabetes. The many gaps in the implementation of the National Diabetes Prevention Program (NDPP) can be characterized as due to macro-level barriers (failures of pay-for-performance reimbursement, an undersupply of lifestyle change programs), micro-level barriers (low and disparate reach, low referral and retention rates in the program), variable fidelity in implementation, and limitations of a one-size-fits-all intervention. All of these issues point to a need for reexamining strategies for diabetes prevention in the U.S., which is yet to show benefits or value at the population level. This article details how prediabetes is currently suboptimally addressed in clinical practice and communities in the U.S. and articulates why there is an urgent need to rethink our approach to addressing prediabetes, possibly through integration of synergistic individual- and societal-levels approaches.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2Life StyleHumansPrediabetic StateUnited States

Identifiers

PMID40267363
PMCPMC12094191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.